IRIS
FICORELLA, Corrado
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.503
AS - Asia 6.620
EU - Europa 6.314
SA - Sud America 861
AF - Africa 106
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 26.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.357
SG - Singapore 2.857
IE - Irlanda 1.514
CN - Cina 1.420
RU - Federazione Russa 1.322
TR - Turchia 748
BR - Brasile 735
DE - Germania 700
HK - Hong Kong 633
SE - Svezia 548
VN - Vietnam 548
IT - Italia 541
UA - Ucraina 438
GB - Regno Unito 415
FR - Francia 255
FI - Finlandia 236
IN - India 98
CA - Canada 80
CZ - Repubblica Ceca 79
PL - Polonia 58
JP - Giappone 57
NL - Olanda 57
BD - Bangladesh 49
MX - Messico 46
BE - Belgio 40
AR - Argentina 37
IQ - Iraq 35
ZA - Sudafrica 35
ES - Italia 29
MA - Marocco 23
EC - Ecuador 21
ID - Indonesia 18
UZ - Uzbekistan 17
CO - Colombia 16
AT - Austria 15
PY - Paraguay 14
VE - Venezuela 14
AU - Australia 13
AE - Emirati Arabi Uniti 12
IL - Israele 11
KR - Corea 11
CL - Cile 10
JO - Giordania 10
KE - Kenya 10
PK - Pakistan 10
RO - Romania 10
SA - Arabia Saudita 10
TN - Tunisia 10
AZ - Azerbaigian 8
EU - Europa 8
MY - Malesia 8
NP - Nepal 8
PH - Filippine 8
PT - Portogallo 8
TH - Thailandia 8
EG - Egitto 7
LT - Lituania 7
BG - Bulgaria 6
DZ - Algeria 6
EE - Estonia 6
PE - Perù 6
RS - Serbia 6
BO - Bolivia 5
CH - Svizzera 4
JM - Giamaica 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AL - Albania 3
AO - Angola 3
BN - Brunei Darussalam 3
CG - Congo 3
DO - Repubblica Dominicana 3
HN - Honduras 3
IR - Iran 3
KH - Cambogia 3
KZ - Kazakistan 3
LY - Libia 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CR - Costa Rica 2
DM - Dominica 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
MD - Moldavia 2
MN - Mongolia 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BF - Burkina Faso 1
BW - Botswana 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GF - Guiana Francese 1
Totale 26.410
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.682
Chandler 1.617
Singapore 1.528
Dublin 1.514
San Jose 1.211
Dallas 1.149
Ashburn 716
Hong Kong 621
Santa Clara 544
Boardman 532
Izmir 360
The Dalles 344
Council Bluffs 294
Wilmington 293
Nanjing 280
New York 276
Princeton 240
Lawrence 239
Ann Arbor 235
San Mateo 224
Moscow 216
Beijing 214
Ho Chi Minh City 177
Los Angeles 140
Hanoi 129
Munich 120
Lauterbourg 116
Nanchang 98
Milan 92
Seattle 86
Bremen 77
Brno 75
São Paulo 73
Columbus 68
Helsinki 68
Shenyang 64
Des Moines 59
Woodbridge 58
Dearborn 55
Tianjin 55
Tokyo 54
Frankfurt am Main 50
Verona 50
Warsaw 50
Hefei 49
L'aquila 49
Hebei 44
Amsterdam 43
Orem 41
Brussels 40
London 37
Kunming 36
Rome 35
Dong Ket 34
Jinan 33
Stockholm 33
Brooklyn 31
Atlanta 30
Jiaxing 30
Norwalk 30
Montreal 29
San Francisco 29
Hangzhou 28
Philadelphia 28
Zhengzhou 28
Falkenstein 26
Denver 25
Johannesburg 25
Chicago 24
Guangzhou 23
Houston 22
Changsha 21
Phoenix 21
Pune 21
Shanghai 21
Chennai 20
Da Nang 20
Mountain View 20
Rio de Janeiro 20
Boston 19
Ningbo 18
Poplar 18
Aquila 17
Haiphong 17
Belo Horizonte 16
Brasília 16
Casablanca 16
Tashkent 15
Toronto 15
Falls Church 14
Lappeenranta 14
Manchester 13
Auburn Hills 12
Berlin 12
Fremont 12
L’Aquila 12
Mexico City 12
Nuremberg 12
Düsseldorf 11
Guayaquil 11
Totale 17.491
Salva come PNG Salva come JPEG
Nome #
Breast cancer and psychological resilience among young women 289
The supportive care task force at the University of L'Aquila: 2-years experience 209
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 194
Emotional Impact of Breast Cancer Treatment: cross-sectional study on level of anxiety, anger, psychological distress and depression in 2-years perspective 183
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 179
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 174
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 171
Does pain intensity predict a poor opioid response in cancer patients? 168
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 168
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 166
Psychological impact of clinical treatment after breast cancer diagnosis in younger patients (38–50 age range): An explorative 3-year observational study 164
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 163
Concurrent RAS and RAS/BRAF V600E variants in colorectal cancer: more frequent than expected? 162
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer 161
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 157
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 154
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer 153
Tapentadol in cancer pain management: a prospective open-label study 150
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 150
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 149
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 149
Oncology together for L'Aquila: early resumption of integrated oncological activities after the earthquake 147
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 147
Efficacy and safety of deep, continuous palliative sedation at home: A retrospective, single-institution study 146
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 145
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer 144
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 144
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 143
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 143
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay 142
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 141
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 140
Predictive Features of Resilience in Early Breast Cancer Young Patients: experience in Real Life 139
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 139
Pain evaluation and management: a survey of Italian radiotherapists 138
Circulating micrornas as prognostic and therapeutic biomarkers in breast cancer molecular subtypes 138
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 137
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 136
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, Fir-B/FOx, according to seconde-line treatment and KRAS genotype 136
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 136
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 134
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 134
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 134
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 132
Efficacy of pregabalin in the management of cetuximab-related itch 132
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience 132
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 132
Multimodality treatment in metastatic gastric cancer: From past to next future 132
What Is Known about Theragnostic Strategies in Colorectal Cancer 130
Evaluation of prognostic factors for survival in transverse colon cancer 130
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer 129
Meccanismo d’azione e farmacologia di nuovi composti organometallici nel trattamento del carcinoma del colon-retto. 129
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer 128
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 128
Low morphine doses in opioid-naive cancer patients with pain 127
Integrating oncology and palliative home care in Italy: the experience of the "L'Aquila per la Vita" Home Care Unit 127
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 127
Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors 127
Poker association of weekly alternating 5-fluorouracil, irinotecan,bevacizumab and oxaliplatin (FIrB/FOx) in first line treatment of metastatic colorectal cancer: a phase II study 126
Assessment and treatment of symptoms among italian medical oncologists 126
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients 126
Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law 126
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line 125
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 125
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen 125
Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib. 124
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 124
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 123
Novel P53 mutations detected by FAMA in colorectal cancers 122
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain 122
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 122
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 122
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management 122
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases 122
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 121
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation 121
Switching from Transdermal Drugs: An Observational "N of 1" Study of Fentanyl and Buprenorphine 120
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 120
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 120
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 120
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 120
Cerebral metastasis from ovarian cancer treated with a multidisciplinary approach. Case report and review of literature 119
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 119
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy 118
Can malignant bowel obstruction in advanced cancer patients be treated at home ? 118
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human cancer cells 118
Biological Function of Oncogenic KRAS In Promoting Angiogenesis 118
NEW MUTATIONS AND PROTEIC VARIANTS OF NBS1 ARE IDENTIFIED IN CANCER CELL LINES 117
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice 117
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 117
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 117
Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective 116
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 116
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 116
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 116
Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifene 115
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 115
Cancer care after natural disaster: Different countries, similar problems 115
Sleep Disturbances in Patients with Advanced Cancer in Different Palliative Care Settings. 114
Choice of chemotherapy schedules in elderly patients (> 75 years) with metastatic colorectal cancer (mcrc) according to comorbidity 114
Totale 13.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021101 0 0 0 0 0 0 0 0 0 0 0 101
2021/20221.333 57 115 223 68 62 24 26 91 85 33 105 444
2022/20234.568 315 300 71 492 444 471 4 298 1.943 21 125 84
2023/20241.080 151 56 49 126 75 297 11 97 2 46 35 135
2024/20254.726 120 87 434 222 641 410 616 349 1.057 219 335 236
2025/20268.679 426 926 686 1.124 904 706 1.463 313 748 912 449 22
Totale 26.715